I analyze Scholar Rock's promising Phase 3 results for SMA drug, but warn of financial challenges and recommend a Hold rating ...

The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor ...

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients ...

Use of SGLT2 inhibitors, compared with DPP4 inhibitors, was associated with a lower risk for total cardiovascular disease ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

Novo Nordisk’s (NVO) next-gen weight loss therapy, CagriSema, caused up to ~23% of weight loss compared to ~16% of weight ...

"Since our lead drug targets excess pro-inflammatory TNF-alpha, a primary cause of sarcopenia ... GLP-1 agonists are expected to be the top selling drug class in 2024. 2 The GLP-1 agonist market is ...

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and ...

Imagine a world where diabetes could be treated with a simple pill that essentially reprograms your body to produce insulin ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe e ...

It’s been a minute since Lifehacker looked at the slang of Generation Z—long enough that Generation Alpha has had time to develop and spread some of its own special buzzwords and jargon.

We look forward to sharing for rosnilimab, a depleter and agonist targeting PD-1+ T cells, top-line Phase 2b rheumatoid arthritis data in February 2025 and top-line Phase 2 ulcerative colitis data ...